BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 23595698)

  • 1. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
    Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
    Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
    Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease.
    Virgone-Carlotta A; Uhlrich J; Akram MN; Ressnikoff D; Chrétien F; Domenget C; Gherardi R; Despars G; Jurdic P; Honnorat J; Nataf S; Touret M
    Glia; 2013 Oct; 61(10):1645-58. PubMed ID: 23893349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
    Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
    Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
    Chan HH; Kumar S; Zhuo L
    Eur J Pharmacol; 2013 Sep; 715(1-3):405-13. PubMed ID: 23652161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
    Steiner B; Winter C; Hosman K; Siebert E; Kempermann G; Petrus DS; Kupsch A
    Exp Neurol; 2006 Jun; 199(2):291-300. PubMed ID: 16360152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
    Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
    Liu WG; Lu GQ; Li B; Chen SD
    Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
    Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
    Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
    Tripanichkul W; Sripanichkulchai K; Finkelstein DI
    Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
    Jin F; Wu Q; Lu YF; Gong QH; Shi JS
    Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
    Savolainen MH; Albert K; Airavaara M; Myöhänen TT
    Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.